Reading Time: 2 minutes
The dominance in the market for diabetes and obesity therapies has propelled the Danish pharmaceutical company Novo Nordisk (i.) to the top of Europe. However, competitive pressure from U.S. rivals is increasing, while at the same time, political and financial pricing pressure in core markets is on the rise. In this context, I believe that the recently announced strategic alliance with Anthropic could be a groundbreaking milestone for the long-term perspective. AI can shorten the time-consuming research phase and administrative hurdles in the approval...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
